Akari Therapeutics plc ADS (NASDAQ: AKTX) last traded at $7.90, down 7.49% on the session. The quote above updates while this page is open; the figures below are drawn from Akari Therapeutics plc ADS’s own filings and are restated only when a new one is published.
Akari Therapeutics plc ADS trades on NASDAQ under the ticker AKTX. Its market capitalisation is $1.23 trillion.
Valuation measures for Akari Therapeutics plc ADS, derived from the latest quote and its most recent SEC filing.
| Market cap | $1.23T |
|---|---|
| Enterprise value | $1.23T |
| Price / book | 66173.29 |
| Beta | 1.89 |
Trailing-twelve-month figures tagged in Akari Therapeutics plc ADS's XBRL filings with the SEC.
| Net income (TTM) |
|---|
| -$30.96M |
| EPS (TTM) | $0.00 |
|---|
| Return on equity | -166.50% |
|---|
| Cash | $7.69M |
|---|
Range and volume for AKTX over the past 52 weeks.
| 52-week high | $39.64 |
|---|---|
| 52-week low | $3.02 |
| Volume | 18.5K |
| Average volume | 61.0K |
| Previous close | $8.54 |
Invest a chosen dollar amount in Akari Therapeutics plc ADS with fractional shares.
Start investingCreate an account
Investing involves risk, including possible loss of principal. Nothing here is investment advice or a recommendation to buy or sell AKTX.
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.